Every 10-Q that Artelo Biosciences, Inc. (ARTL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARTL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTL filings page.
Artelo Biosciences, Inc. reported unaudited results for the quarter and six months ended June 30, 2026. The clinical-stage biopharmaceutical company remains pre-revenue and recorded a net loss of $2.4 million for the quarter and $5.4 million for the first half of 2026, broadly similar to the prior-year period. Operating expenses for the six months were $5.2 million, with $3.5 million in general and administrative costs and $1.6 million in research and development, reflecting reduced CAReS trial spending versus 2025.
Liquidity improved following equity financings and debt settlements. Cash and cash equivalents increased to $4.2 million at June 30, 2026 from $0.6 million at year-end 2025, and total liabilities fell to $1.5 million from $4.1 million, shifting stockholders’ equity from a deficit of $(1.3) million to positive $5.0 million. In March 2026 Artelo raised gross proceeds of $10.997 million (net $10.033 million) via a common stock and warrant private placement and fully settled its March 2026 convertible notes, recording a small gain on extinguishment of debt.
The company established a $75.0 million Form S-3 shelf and a $6.53 million at-the-market program, issuing 142,860 ATM shares for $0.174 million by June 30, 2026. Despite these actions, management disclosed that current resources are insufficient to fund operations for 12 months without additional capital, and expressed substantial doubt about Artelo’s ability to continue as a going concern.
Artelo Biosciences reported a net loss of $2.96M for the three months ended March 31, 2026, compared with $2.37M a year earlier, as general and administrative costs rose and research and development spending shifted lower. Operating expenses reached $2.69M, driven mainly by higher professional fees and stock-based compensation. Cash and cash equivalents jumped to $10.27M from $0.60M at year-end, largely due to a March 2026 private placement that generated gross proceeds of $10.997M (net $10.03M) through common shares and a large package of pre-funded and common warrants. The company also issued three convertible notes with variable conversion features, recognized a derivative liability of $0.58M, and recorded a day-one loss of $0.46M on one note. Despite the improved liquidity, management states that recurring losses and funding needs raise substantial doubt about Artelo’s ability to continue as a going concern within one year.
Artelo Biosciences (ARTL) filed its Q3 2025 10‑Q, highlighting liquidity pressure and continued R&D spend. The company reported a net loss of $8.7 million for the nine months ended September 30, 2025, driven by operating expenses of $8.6 million. Cash and cash equivalents were $1.7 million as of September 30, 2025, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
To fund operations, Artelo executed multiple capital raises: $0.9 million in unsecured convertible notes on May 1; a June private placement with $1.4 million gross proceeds; an at‑the‑market program that sold 50,858 shares for $442,000 net in Q3; and a September underwritten offering with ~$3.0 million gross ($2.87 million net). Subsequent events include an October 1 underwritten offering of ~$2.0 million gross and an October 28 note/warrant financing of $690,000 in notes plus 438,182 warrants at $3.40. Shares outstanding were 2,018,746 as of November 10, 2025. The company also held $325,000 fair value of SOL digital assets (cost $250,000), which flows through earnings under ASU 2023‑08.
Artelo Biosciences reported a quarterly net loss of $3.221 million and a six-month net loss of $5.593 million, while holding $2.066 million in cash and cash equivalents as of June 30, 2025. Current liabilities increased to $5.712 million, producing a working capital deficit of $3.479 million, and management discloses substantial doubt about the Company’s ability to continue as a going concern within one year.
The company completed financings including $900,000 of convertible notes bearing 12% interest (net carrying value $791,000), a June private placement that generated $1.425 million gross ($1.079 million net), an ATM sales agreement for up to $6.5 million, and an expected August PIPE targeting approximately $9.475 million. The Company adopted a Digital Asset Treasury strategy to acquire Solana (SOL); under ASU 2023-08 SOL fair-value changes will flow through net income.